Healthy Skepticism Library item: 19129

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Sales Through Retail Pharmacies (Twelve months to November 2010)
ims 2011 Jan
http://view.respond.imshealth.com/?j=fe54157876630d7e7c17&m=fef31377726304&ls=fdfa17757666017475127374&l=fe9615727662037d73&s=fe21127975600c75701171&jb=ffcf14&ju=fe1c1671726d0c7b771d77&r=0

Full text:

Sales Through Retail Pharmacies (Twelve months to November 2010)*

NORTH AMERICA $243.0 billion up 3%
U.S.A. $223.8 billion up 3%
CANADA $19.3 billion up 3%

EUROPE (TOP 5) $106.9 billion up 1%
GERMANY $34.9 billion up 3%
FRANCE $28.1 billion up 0%
ITALY $15.8 billion up 0%
SPAIN $14.5 billion up 0%
UK $13.6 billion up 2%

JAPAN (including hospitals) $85.1 billion up 1%

CHINA (hospital) $31.6 billion up 23%

LATIN AMERICA (TOP 4) $35.0 billion
BRAZIL $17.2 billion up 20%
MEXICO $7.7 billion up 1%
VENEZUELA $6.2 billion up 31%
ARGENTINA $3.9 billion up 25%

AUSTRALIA/NZ $9.6 billion up 6%

The top 5 therapy classes at ATC3 level in the 12 months to November 2010 were:

1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N5A – Antipsychotics
4. N6A – Antidepressants & mood stabilisers
5. C9C – Angioten-II Antag, Plain

The top 5 products in the 12 months to November 2010 were:

1. Lipitor
2. Plavix
3. Nexium
4. Seretide
5. Crestor

The top 5 corporations in the 12 months to November 2010 were:

1. Pfizer
2. Novartis
3. AstraZeneca
4. Merck & Co
5. GlaxoSmithKline

View our full selection of Pharma Market Sales and Growth Reports in the IMS Store here: http://www.store.imshealth.com/s.nl/sc.1/category.10/.f